基因检测、保险歧视与医学研究:美国可向其他国家借鉴的经验
本文为视角文章,讨论基因检测带来的保险歧视担忧可能阻碍临床研究招募,介绍英国、法国等国家平衡保险公司与研究参与者利益的举措,并呼吁监管与行业共同建立保险定价自愿暂停机制以保护研究参与者。
要点
- 对基因信息被披露给保险公司的担忧可能阻碍涉及基因检测的临床研究招募。
- 英国、法国等国家采取了更好平衡保险公司与研究参与者利益的举措。
- 作者呼吁监管与行业领导共同建立保险定价自愿暂停机制以保护研究参与者。
核心结论
- 美国精准医学计划如All of Us若要成功,必须确保参与分享基因数据的美国人不会在人寿、残疾和长期保险方面受到惩罚。
- 作者呼吁监管与行业领导共同建立保险定价自愿暂停机制,以保护研究参与者。
研究设计与样本
- 本文为视角文章,讨论世界各国(如英国和法国)为更好平衡保险公司与研究参与者利益而采取的若干举措,并说明美国可如何借鉴。
主要发现
- 对基因信息被意外披露给保险公司及可能发生基因歧视的担忧,可能阻碍涉及基因检测的临床研究招募个体。
- 英国和法国等国家采取了更好平衡保险公司与研究参与者利益的举措。
临床怎么用
- 作者呼吁监管与行业领导共同建立保险定价自愿暂停机制,以保护研究参与者。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
While genetic testing may be the gateway to the future of medicine, it also poses challenges for individuals, especially in terms of differentiated treatments on the basis of their genetic characteristics. The fear of unwanted disclosure to insurers and the possibility of genetic discrimination can hamper the recruitment of individuals for clinical research that involves genetic testing. Precision medicine initiatives, such as All of Us, are proliferating in the United States. In order to succeed, however, they must ensure that the millions of Americans recruited to share their genetic data are not penalized with regard to life, disability and long-term insurance coverage. In this Perspective, we discuss several initiatives adopted by countries around the world, such as the United Kingdom and France, that better balance the interests of insurers and research subjects, and explain how the United States might learn from them. We call for regulatory and industry leadership to come together to establish a voluntary moratorium on insurance pricing with the aim of protecting research participants.
引用
- Bélisle-Pipon JC, Vayena E, Green RC, et al. Genetic testing, insurance discrimination and medical research: what the United States can learn from peer countries. Nat Med. 2019. PMID: 31388181. doi:10.1038/s41591-019-0534-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。